482 assets in Prostate Cancer

Therapeutic assets addressing Prostate Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
[18F]F-RESCA-T4 Prostate Cancer	RenJi Hospital	P2/3	CCC (48)
1-PIPERIDINEETHANOL, .ALPHA.-((2-NITRO-1H-IMIDAZOL-1-YL)METHYL)-, HYDROCHLORIDE (1:1), (.ALPHA.R)- Prostate Cancer	The Christie NHS Foundation Trust	P2	CCC (48)
64cu-sar-bbn Prostate Cancer	St Vincent's Hospital, Sydney	P2	CCC (48)
[68ga]ga-nota-rt4 Prostate Cancer	RenJi Hospital	P2/3	CCC (48)
[68ga]ga-nota-t4 Prostate Cancer	RenJi Hospital	P2/3	CCC (48)
[68ga]p16-093 Prostate Cancer	Five Eleven Pharma, Inc.	P1/2	CCC (48)
68ga-p16-093 Prostate Cancer	Peking Union Medical College Hospital	P2/3	CCC (48)
Apsolol Prostate Cancer	Zhongda Hospital	P2	CCC (48)
Biodfence G3 Prostate Cancer	AdventHealth	P3	CCC (48)
Cryopreserved Umbilical Cord Allograft Prostate Cancer	Hackensack Meridian Health	P2/3	CCC (48)
Dual-Target Antigen-Selected Car-Nk Prostate Cancer	Essen Biotech	P1/2	CCC (48)
Eb-Select Single-Target Car-Nk Cells Prostate Cancer	Essen Biotech	P1/2	CCC (48)
Exemestane Prostate Cancer	OHSU Knight Cancer Institute	P2	CCC (48)
Fampridine Prostate Cancer	John Elfar	P2/3	CCC (48)
F-Dcfpyl Prostate Cancer	H. Lee Moffitt Cancer Center and Research Institute	P2/3	CCC (48)
fp-014 Prostate Cancer	Foresee Pharmaceuticals Co., Ltd.	P3	CCC (48)
gsk5458514 Prostate Cancer	GlaxoSmithKline	P1/2	CCC (48)
gsk5471713 Prostate Cancer	GlaxoSmithKline	P1/2	CCC (48)
Memantine Hydrochloride Prostate Cancer	Bin Xu	P2	CCC (48)
Nelfinavir Prostate Cancer	Medical University of South Carolina	P1/2	CCC (48)
OTL-38 Prostate Cancer	Indiana University	P2	CCC (48)
Radium Dichloride Prostate Cancer	Memorial Sloan Kettering Cancer Center	P2	CCC (48)
Rintatolimod Prostate Cancer	Roswell Park Cancer Institute	P2	CCC (48)
Sumarotene Prostate Cancer	CuraCell TX AB	P1/2	CCC (48)
Tb-Psma-I&T Prostate Cancer	Rabin Medical Center	P1/2	CCC (48)
Testosterone Enantate Prostate Cancer	Australian and New Zealand Urogenital and Prostate Cancer Trials Group	P2	CCC (48)
Tivozanib Prostate Cancer	University of Florida	P2	CCC (48)
Triptoreline Prostate Cancer	Universitaire Ziekenhuizen KU Leuven	P2/3	CCC (48)
Uromitexan Prostate Cancer	CuraCell TX AB	P1/2	CCC (48)
68Ga-PSMA-CYC Prostate Cancer	First Affiliated Hospital of Fujian Medical University	P1/2	CC (47)
Anti-Steap1 Car T-Cells Prostate Cancer	Fred Hutchinson Cancer Center	P1/2	CC (47)
Avelumab Prostate Cancer	National Cancer Institute (NCI)	P2	CC (47)
Ivuxolimab Prostate Cancer	M.D. Anderson Cancer Center	P1/2	CC (47)
shr7280 Prostate Cancer	Jiangsu HengRui Medicine Co., Ltd.	P1	CC (47)
Tyk-00540 Prostate Cancer	TYK Medicines, Inc	P1/2	CC (47)
vb15010 Prostate Cancer	Zhejiang Yangli Pharmaceutical Technology Co., Ltd.	P1/2	CC (47)
177lu-p17-088 Prostate Cancer	First Affiliated Hospital of Fujian Medical University	P2	CC (46)
177Lu-PSMA-I&T Prostate Cancer	Medical University of Vienna	P2	CC (46)
2141-v11 antibody Prostate Cancer	Memorial Sloan Kettering Cancer Center	P2	CC (46)
68ga-hbed-ipsma Prostate Cancer	Memorial Sloan Kettering Cancer Center	P2	CC (46)
ac0010ma Prostate Cancer	Sorrento Therapeutics, Inc.	P2	CC (46)
Adrenocorticotropic Hormone Prostate Cancer	Astellas Pharma Global Development, Inc.	P2	CC (46)
Artemicoffee Prostate Cancer	Zin W Myint	P2	CC (46)
Atirmociclib Prostate Cancer	Pfizer	P2	CC (46)
azd6738 Prostate Cancer	University of Michigan Rogel Cancer Center	P2	CC (46)
Bacillus Calmette-Guerin Live Antigen, Unspecified Substrain Prostate Cancer	Cellvax Therapeutics Inc	P2	CC (46)
Benzamide, 3-((3-Endo)-8-(2-((Cyclohexylmethyl)((2S)-2,3-Dihydroxy-1-Oxopropyl)Amino)Ethyl)-8-Azabicyclo(3.2.1)Oct-3-Yl)- Prostate Cancer	HealthPartners Institute	P2	CC (46)
Biodfence G3 Placental Tissue Membrane Prostate Cancer	University of Miami	P2	CC (46)
Darotamine Prostate Cancer	Jiangsu HengRui Medicine Co., Ltd.	P2	CC (46)
Debio 4228 Prostate Cancer	Debiopharm International SA	P2	CC (46)

Showing 201 to 250 of 482 assets

PreviousPage 5 of 10Next